PUBLIC COMPANY
saveEMERGENT
USupdated 4mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trialWith just over $10 million in cash available to fuel operations through the end of the year, Longeveron is undertaking a strategic review after the failure of a cardiovascular study.biospace · 16h ago
- Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting the cash-strapped biotech to “review all options” for the business.fiercebiotech · 1d ago
- Sling catches $123M series C for thyroid eye disease pillSling Therapeutics is advancing the first late-stage oral drug for thyroid eye disease that, if approved, could compete against Amgen and Viridian Therapeutics.biospace · 1d ago
- Summit, BioNTech, more headline WCLC with next-gen lung cancer drugsBioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new fi…biospace · 3d ago
- Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’Positive topline results from a second straight study in generalized anxiety disorder shift the narrative for Definium Therapeutics’ DT120 to commercialization, Jefferies analysts said Monday, whil…biospace · 3d ago
- Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stockTyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premar…fiercebiotech · 8d ago
- Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancerInhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.biospace · 9d ago
- FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancerIn a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new…fiercebiotech · 9d ago
- AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialAbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multip…fiercebiotech · 14d ago
- Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts splitSafety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.biospace · 17d ago
comments(0)
5-min edit window · permanent after that